Halozyme to Participate in the BofA Securities 2025 Healthcare Conference | HALO Stock News
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will present at the BofA Securities 2025 Healthcare Conference on May 13 at 4:20pm PT. A live audio webcast will be available on the company's website, with replays for 90 days. Halozyme specializes in innovative drug delivery solutions, including its ENHANZE® technology, and has partnered with major pharmaceutical companies. The company is headquartered in San Diego, CA, with additional offices in Ewing, NJ, and Minnetonka, MN.
, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference.
The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET.
A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.comand connect with us on LinkedIn and Twitter.
Contacts:
TramBui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
SOURCE Halozyme Therapeutics, Inc.